1st all-in-one percutaneous tracheostomy reduces insertion trauma & hospital infections; 510(k); top reimbursement; 95% margins; $2Bmarket
•Break-even possible within 2 yrs of revenue start-up
•Only $5.5M total investment to cash flow positive
•Our KOL Advisor, past President/Board Chairman American Thoracic Society: "Could make a real difference in complications, especially procedural trauma and infection."
•Decrease hospital costs & mortality
•Very attractive revenue ramp-Bass model
•Patent pending 1st all-in-one device